Munari04: Cayenne Pepper Cataplasm - Safety Study

Sponsor
University of Primorska (Other)
Overall Status
Completed
CT.gov ID
NCT03440125
Collaborator
S2P, Science to Practice, Ltd. (Other), Comenius University (Other), Wilhelminenspital Vienna (Other), Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation (Other)
30
2
3
9
15
1.7

Study Details

Study Description

Brief Summary

The beneficial analgesic effects of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper, are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. In Vienna and lower Austria, a Cayenne Pepper Cataplasm (CPC) application containing Cayenne pepper and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. However, a concern about the safety of such applications was recently raised.

Therefore, the aims of the present study are to evaluate the effects of 10x 20min CP cataplasm application as a single treatment or in combination with electrical stimulation and massage on selected functional and molecular parameters on i) healthy subjects and ii) subjects suffering from low back pain.

Condition or Disease Intervention/Treatment Phase
  • Drug: Cayenne Pepper topical
  • Device: Electrical stimulation
  • Procedure: Massage
Phase 1/Phase 2

Detailed Description

Musculoskeletal diseases, such as neck and low back pain, are widespread disorders in many developed countries. Their management is challenging, and it may have mounting socioeconomic burden. Several evidences in the literature demonstrate the efficacy of many therapeutic strategies in the treatment of these conditions, based on pharmacological or surgical interventions. Physical medicine therapies are good alternatives that may have beneficial effects, especially when used as first line of intervention before approaching more expensive pharmacological or invasive medications. The beneficial analgesic effects of Applicatio Epispasticorum of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper (CP), are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. They are also used in pain involving joints caused by osteoarthritis. A galenic preparation composed of rubefacient substances of vegetable origin, which generated vasodilation and increase in blood circulation on the treated areas, was first prescribed in 1909 by Dr. Giuseppe Munari to treat pain of various areas of the locomotive system. He proposed a method based on applications prepared according to his own galenic formula that have become famous all over Italy and Europe. In Vienna and lower Austria, a Munari-like application containing CP and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. The research on responses to CPC applications, particularly in combination with other modalities is scarce.

Therefore, the aims of the present study are firstly to evaluate the effects of 10x 20min CP cataplasm application on selected functional and molecular parameters on healthy subjects. Then, the same applications will be used on subjects suffering from low back pain (LBP) - both as a single treatment and in combination with electrical stimulation and massage.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Cayenne Pepper Cataplasm Application and Potential Side Effects
Actual Study Start Date :
Mar 15, 2016
Actual Primary Completion Date :
Nov 15, 2016
Actual Study Completion Date :
Dec 15, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Healthy

Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.

Drug: Cayenne Pepper topical
20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
Other Names:
  • Cayenne Pepper Cataplasm application
  • Experimental: LBP patients - CPC Group

    Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).

    Drug: Cayenne Pepper topical
    20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
    Other Names:
  • Cayenne Pepper Cataplasm application
  • Experimental: LBP patients - CPC and ES/M Group

    Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.

    Drug: Cayenne Pepper topical
    20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
    Other Names:
  • Cayenne Pepper Cataplasm application
  • Device: Electrical stimulation
    Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
    Other Names:
  • Neuromuscular Electrical Stimulation (NMES)
  • Procedure: Massage
    10 minutes of classical massage of low back pain area.
    Other Names:
  • Classical massage
  • Outcome Measures

    Primary Outcome Measures

    1. Change in concentration of circulating biomarkers of inflammation, neudroendocrine stress and blood vessel activation [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      The blood analysis will include standard analysis of hemogram, C-reactive proteins, creatine-kinase, sedimentation, albumin and cortisol. Enzyme-linked immunosorbent assay (ELISA) will include Tumor necrosis factor-Alpha, Interleukin-6, Leukotriene B4 and P-Selectine. Additionally, microRNA analysis will be performed (gene numbers: 1, 21, 23, 25, 103, 126, 133, 146, 155, 199a, 199b, 191, 206, 451.

    2. Change in systolic and diastolic blood pressure [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      Systolic and diastolic blood pressure [mmHg], measured at both sides of the body with blood pressure gauge

    3. Heart rate [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      Heart rate (bpm), measured with heart rate monitor belt.

    Secondary Outcome Measures

    1. 36-Item Short Form Survey (SF-36) [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      The Short Form (36) Health Survey (SF-36) is a patient-reported survey of patient health. It consists of eight scaled scores, which are the weighted sums all questions in their respective section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the higher is the disability.

    2. Change in pain perception [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      Pain perception during rest and movement assessed with visual analogue scale (0-10). 0 represents no pain, and 10 represents severe pain.

    3. EQ-5D- 5L questionnaire [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      EQ-5D- 5L questionnaire includes following aspects: mobility, care, usual activities, pain/discomfort, anxiety/depression, crosswalk-index, self-feeling of health. Each aspect is evaluated on a 1-5 scale, with following descriptions of levels: having no problems, having slight problems, having moderate problems, having severe problems and being unable to do/having extreme problems. Visual analogue scale is the second part of the questionnaire, asking to mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. There are notes at the both ends of the scale that the bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) corresponds to "the best health you can imagine".

    4. Oswestry disability index (ODI) [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      ODI will be used only in LBP arms (Arm 2 and 3). ODI is commonly used by clinicians and researchers to quantify disability for low back pain.

    5. Skin Sensory Function [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      Skin sensory function will be assessed by 2-point discrimination test (which is carried out using two pins, oriented in medial-lateral direction and pressed perpendicularly to the skin, with the medial pin being 3 cm laterally from the L3 spinal process. The subject is asked to report whether he/she felt one or two pins) and mono filament/light touch sensitivity tests (monofilaments calibrated to 0.025, 0.07, 2, 5, and 10 grams The subject is asked to report when he/she felt touching the skin with a monofilament 3 cm laterally from L3 spinal process). The lightest mono filament and the lowest pin inter-distance are take as final outcome measures.

    6. Flexibility [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      Assessment of total spine flexibility (forward bend test) and separately for the lumbar part (Schober's test) and thoracic part.

    7. Skin Temperature [Before the application, 45 minutes after 10th application and 48 hours after 10th application]

      Skin temperature [°C] at the site of application (low back) and at the control part of the body (neck), measured with a laser thermometer.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Chronic low back pain (>3 months)

    • Body mass index below 35 kg/mˇ2

    Exclusion Criteria:
    • pregnancy

    • sensibility disorders (e.g. due to neurological disease)

    • injuries, open wounds or rash in intervention area

    • known hypersensitivity against the applied substances

    • HIV, Hepatitis C and other due blood communicable infectious diseases

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Facultiy of Physical Education and Sports, Comenius University of Bratislava Bratislava Slovakia 81806
    2 Faculty of Health Sciences Izola Slovenia 6310

    Sponsors and Collaborators

    • University of Primorska
    • S2P, Science to Practice, Ltd.
    • Comenius University
    • Wilhelminenspital Vienna
    • Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation

    Investigators

    • Principal Investigator: Nejc Šarabon, PhD, Faculty of Health Sciences, University of Primorska, Slovenia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nejc Sarabon, Dean of Faculty, University of Primorska
    ClinicalTrials.gov Identifier:
    NCT03440125
    Other Study ID Numbers:
    • UP-MunariStudy
    First Posted:
    Feb 20, 2018
    Last Update Posted:
    Feb 20, 2018
    Last Verified:
    Feb 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nejc Sarabon, Dean of Faculty, University of Primorska
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 20, 2018